Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 9:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Particle Clear all
Completed Phase 3 Interventional Results available

GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study

NCT02525861
View directory record Official record
Conditions
Alpha1-antitrypsin Deficiency
Interventions
GLASSIA
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
17
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 7, 2026, 9:17 AM EDT
Completed Not applicable Interventional Results available

Late Effects of Proton Radiation Therapy in Patients With Low-Grade Glioma

NCT00681473
View directory record Official record
Conditions
Low Grade Gliomas
Interventions
Proton Radiation Therapy
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2017 · Synced Sep 7, 2026, 9:17 AM EDT
Completed Not applicable Interventional Results available

Aerosol Particle Concentrations Among Different Oxygen Devices for Spontaneous Breathing Patients With Tracheostomy

NCT04654754
View directory record Official record
Conditions
Transmission, Patient-Professional
Interventions
high-flow high humidity oxygen device with tracheostomy adapter
Device
Lead sponsor
Jie Li
Other
Eligibility
18 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Sep 7, 2026, 9:17 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)

NCT02971007
View directory record Official record
Conditions
Vulvovaginitis, Yeast Infection, Yeast Infection Vaginal, Candidiasis, Vulvovaginal
Interventions
Oral Encochleated Amphotericin B (CAMB), Fluconazole
Drug
Lead sponsor
Matinas BioPharma Nanotechnologies, Inc.
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Sep 7, 2026, 9:17 AM EDT
Not listed Phase 2 Interventional

REMUNE HIV/AIDS Vaccine Phase II Pediatric Safety & Efficacy Clinical Study

NCT02291809
View directory record Official record
Conditions
HIV/AIDS
Interventions
REMUNE
Biological
Lead sponsor
Immune Response BioPharma, Inc.
Industry
Eligibility
3 Months to 16 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2016 · Synced Sep 7, 2026, 9:17 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

NCT04228783
View directory record Official record
Conditions
Ebola
Interventions
Ad26.ZEBOV, MVA-BN-Filo, Placebo
Biological
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years to 50 Years
Enrollment
974 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
7
States / cities
Mobile, Alabama • Tempe, Arizona • Lexington, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 7, 2026, 9:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults

NCT03341754
View directory record Official record
Conditions
Malaria
Interventions
D/ChAd63-CA, D/ChAd63-CAT, Infectivity Control (IC) Group
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Bethesda, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Sep 7, 2026, 9:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Particle Size, Formulation and Food on the Pharmacokinetics of GDC-0032 in Healthy Volunteers

NCT01980953
View directory record Official record
Conditions
Healthy Volunteer
Interventions
GDC-0032 Phase III Tablet, GDC-0032 Tablet, GDC-0032 Capsule
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Sep 7, 2026, 9:17 AM EDT
Recruiting Phase 3 Interventional

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

NCT04892173
View directory record Official record
Conditions
Carcinoma, Squamous Cell
Interventions
JNJ-90301900 (NBTXR3), Cetuximab, Radiation Therapy
Drug · Radiation
Lead sponsor
Johnson & Johnson Enterprise Innovation Inc.
Industry
Eligibility
60 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
26
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 23 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 7, 2026, 9:17 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT04704505
View directory record Official record
Conditions
Prostate Adenocarcinoma, Metastatic Prostate Adenocarcinoma, Castration-resistant
Interventions
radium-223, Bipolar Androgen Therapy (BAT)
Radiation · Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Sep 7, 2026, 9:17 AM EDT
Not listed Not applicable Interventional

VIA Disc NP Pilot for Patients With Symptomatic Degenerated Discs

NCT05201287
View directory record Official record
Conditions
Degenerative Disc Disease, Low Back Pain, Disc Degeneration
Interventions
VIA Disc NP
Other
Lead sponsor
VIVEX Biologics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Larkspur, California • Santa Monica, California • Walnut Creek, California + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2024 · Synced Sep 7, 2026, 9:17 AM EDT
Completed Phase 2 Interventional

Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer

NCT05673811
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Metastatic
Interventions
Nab-paclitaxel, Gemcitabine, VCN-01
Drug · Genetic
Lead sponsor
Theriva Biologics SL
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Newport Beach, California • Sacramento, California • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Sep 7, 2026, 9:17 AM EDT
Withdrawn Phase 2 Interventional

Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer

NCT02143804
View directory record Official record
Conditions
Bladder Cancer, High Grade, Non Muscle Invasive
Interventions
oncolytic adenovirus expressing GMCSF
Biological
Lead sponsor
CG Oncology, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 7, 2026, 9:17 AM EDT
Completed Phase 2 Interventional Results available

Clinical Trial Characterizing the Bioavailability of 1-Octanol in Adults With Ethanol-responsive Essential Tremor

NCT00102596
View directory record Official record
Conditions
Essential Tremor
Interventions
1-Octanol
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
21 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 31, 2012 · Synced Sep 7, 2026, 9:17 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults

NCT02935686
View directory record Official record
Conditions
Healthy
Interventions
Ad26.Mos4.HIV, Clade C gp140 plus adjuvant, Clade C gp140/Mosaic gp140 plus adjuvant, Placebo, gp140 HIV Bivalent Vaccine
Biological · Other
Lead sponsor
Janssen Vaccines & Prevention B.V.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
11
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 7, 2026, 9:17 AM EDT
Completed Phase 1Phase 2 Interventional

LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer

NCT02705196
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
delolimogene mupadenorepvec, gemcitabine, nab-paclitaxel, atezolizumab
Genetic · Drug · Biological
Lead sponsor
Lokon Pharma AB
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Sep 7, 2026, 9:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

VRC 313: A Trivalent Virus-like Particle (VLP) Encephalitis Vaccine (WEVEE) in Healthy Adults

NCT03879603
View directory record Official record
Conditions
Venezuelan Equine Encephalitis, Western Equine Encephalitis, Eastern Equine Encephalitis, Alphavirus Infections
Interventions
VRC-WEVVLP073-00-VP, VRC-GENMIX083-AL-VP
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 7, 2026, 9:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Comparison of Bone Formation With Three Different Bone Graft Materials Following Sinus Graft

NCT01911819
View directory record Official record
Conditions
Inadequate Bone Height in Maxillary Posterior Area
Interventions
Sinus augmentation, Equimatrix, OSSIF-i sem, Bio-oss
Procedure · Drug
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Sep 7, 2026, 9:17 AM EDT
Recruiting Not applicable Interventional

Rectal Arterial Embolization vs Band Ligation for the Treatment of Internal hemOrrhoidS

NCT07559630
View directory record Official record
Conditions
Hemorrhoidal Bleeding, Hemorrhoids, Internal, HAE, RBL
Interventions
Hemorrhoidal Artery Embolization, Rubber Band Ligation
Device · Procedure
Lead sponsor
Jessica K. Stewart, MD
Other
Eligibility
18 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Sep 7, 2026, 9:17 AM EDT
Not listed Not applicable Interventional

Indoor Air Quality Asthma Study: The Effect of Indoor Air Quality and Mitigation of Same on Persistent Asthma

NCT05843045
View directory record Official record
Conditions
Persistent Asthma
Interventions
Indoor Air Quality Mitigation
Device
Lead sponsor
Dayton Children's Hospital
Other
Eligibility
5 Years to 15 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2024 · Synced Sep 7, 2026, 9:17 AM EDT
Recruiting Not applicable Interventional

Genicular Artery Embolization for Knee Osteoarthritis

NCT07537153
View directory record Official record
Conditions
Osteoarthritis, Knee Osteoarthritis
Interventions
Embosphere Microspheres
Device
Lead sponsor
Northwestern University
Other
Eligibility
40 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Sep 7, 2026, 9:17 AM EDT
Terminated Phase 1 Interventional

Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer

NCT04108481
View directory record Official record
Conditions
Colorectal Cancer Metastatic, Colon Cancer, Metastatic Colorectal Cancer, Rectal Cancer, Liver Metastasis Colon Cancer, Colo-rectal Cancer, Colorectal Adenocarcinoma, Colorectal Neoplasms, Liver Metastases, Colorectal Carcinoma
Interventions
Durvalumab, Yttrium-90 RadioEmbolization
Drug · Radiation
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Sep 7, 2026, 9:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Sensitivity of Pharmacokinetics to Differences in Particle Size Distribution of Suspension-based Nasal Sprays

NCT02588326
View directory record Official record
Conditions
Hypersensitivity
Interventions
Mometasone furoate drug formulation (MFF) 1, Mometasone furoate drug formulation (MFF) 2
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 50 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 15, 2021 · Synced Sep 7, 2026, 9:17 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Assessing Durable Antibody Response to HPV Vaccination

NCT05031078
View directory record Official record
Conditions
HPV
Interventions
Gardasil-9, Lidocaine injections
Biological · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 45 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Sep 7, 2026, 9:17 AM EDT